Psy111 - Pharmacoeconomic Evaluation of Biosimilar Recombinant Alpha-Epoetin in the Treatment of Anemia in Hemodialysis Patients

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2686
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Effect of Water Treatment on Anemia in Hemodialysis Patients

Journal of Japanese Society for Dialysis Therapy
1985English

Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodialysis Patients

Renal Failure
MedicineNephrologyCritical CareIntensive Care Medicine
2011English

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment

Clinical medicine. Oncology
2008English

Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis

JAMA - Journal of the American Medical Association
Medicine
2007English

Clinical Efficacy and Safety of SB309, a Biosimilar Recombinant Human Erythropoietin, in the Management of Anemia

Biosimilars
2013English

Anemia in Conventional Hemodialysis: Finding the Optimal Treatment Balance

Seminars in Dialysis
Nephrology
2018English

Iron Deficiency Anemia in Chronic Hemodialysis Patients

Journal of Japanese Society for Dialysis Therapy
1981English

Pharmacoeconomic Analysis of Сosmofer (Iron III - Hydroxide Dextran) in the Treatment of Iron Deficiency Anemia for Chronic Kidney Disease Patients

Pharmacoeconomics: theory and practice
2017English

Effects of Recombinant Human Erythropoietin (R-HuEPO) Treatment on Cardiovascular Hemodynamics in Hemodialysis Patients

Journal of Japanese Society for Dialysis Therapy
1989English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy